FTC Finalizes Consent Order For Ascension-AmSurg Merger
The Federal Trade Commission has completed its review of Ascension Health Alliance’s proposed $3.9 billion acquisition of AmSurg LLC, issuing a final consent order that allows the deal to move forward under specified conditions. The agency’s action closes out a regulatory process that examined how the combination of a major nonprofit hospital system with a large operator of outpatient surgery centers could affect competition in local health care markets.
According to the commission, the consent order was finalized after a public comment period during which the agency reviewed feedback on the proposed terms. Ascension, one of the largest nonprofit health systems in the United States, sought to acquire AmSurg, a company that manages and develops ambulatory surgery centers across multiple states. The FTC’s order is designed to address concerns that the merger could reduce competition for outpatient surgical services in markets where both companies operate, though the commission did not detail specific divestitures or behavioral commitments in its announcement.
The FTC’s consent order process typically requires companies to agree to conditions before a merger can be completed, often including requirements to maintain competition through asset sales, firewalls between business units, or ongoing reporting obligations. Final approval indicates that the commission determined the agreed-upon remedies were sufficient to resolve its antitrust concerns, allowing Ascension and AmSurg to proceed with closing the transaction.
The deal reflects a broader trend of consolidation between hospital systems and outpatient surgical providers, a shift driven in part by the migration of many procedures away from traditional inpatient hospital settings. Ambulatory surgery centers have grown rapidly over the past decade as insurers and patients increasingly favor lower-cost, same-day surgical options for procedures ranging from orthopedic work to gastrointestinal screenings. For large hospital networks, acquiring or partnering with surgery center operators offers a way to capture that shifting volume while expanding their footprint in local markets.
Antitrust regulators have paid closer attention to health care consolidation in recent years, citing concerns that mergers between hospitals, physician groups and ancillary service providers can raise prices and limit patient choice, particularly in regions with few competing options. The FTC and the Department of Justice have both signaled heightened scrutiny of vertical and horizontal deals in the sector, arguing that unchecked consolidation can weaken competitive pressure that keeps costs in check for insurers and, ultimately, patients. Deals involving hospital systems acquiring outpatient facilities have drawn particular interest because they can shift referral patterns and pricing power in ways that are not always immediately visible to consumers.
Industry analysts note that transactions of this size and structure often take months to clear regulatory review, as agencies weigh the potential efficiencies of combined operations against the risk of reduced competition in specific geographic markets. The FTC’s willingness to finalize the order suggests it concluded that the agreed terms adequately addressed those risks, though the commission has in other cases required more extensive remedies or blocked deals outright when it found insufficient safeguards.
Neither Ascension nor AmSurg has publicly detailed how the finalized order will affect the timeline for closing the acquisition or how the companies plan to integrate operations once the deal is completed. The FTC’s announcement did not include additional financial terms beyond the previously disclosed $3.9 billion transaction value.
The announcement was detailed in a press release from the Federal Trade Commission.
